Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
11.70
+0.52 (4.65%)
At close: Mar 16, 2026, 4:00 PM EDT
11.58
-0.12 (-1.03%)
After-hours: Mar 16, 2026, 4:10 PM EDT

Crescent Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-153.94-17.87-36.9-46.69-63.43
Depreciation & Amortization
0.08-0.150.210.26
Stock-Based Compensation
13.31.133.523.866.09
Other Adjustments
82.400.90.830.75
Change in Receivables
-18----
Changes in Accounts Payable
2.080.11-0.1-1.140.02
Changes in Accrued Expenses
5.362.17-1.77-1.72-0.99
Changes in Unearned Revenue
4.16----
Changes in Other Operating Activities
-6.977.18-0.69-1.8-0.19
Operating Cash Flow
-71.53-6.27-34.88-46.46-57.49
Capital Expenditures
-0.92--0.02-0.08-0.01
Purchases of Intangible Assets
-72----
Investing Cash Flow
-72.92--0.02-0.08-0.01
Issuance of Common Stock
321.890.3228.824.1610.72
Repurchase of Common Stock
-0.18----
Net Common Stock Issued (Repurchased)
321.720.3228.824.1610.72
Other Financing Activities
1.27-0.76---
Financing Cash Flow
322.9841.0428.824.1610.72
Net Cash Flow
178.5334.77-6.08-42.38-46.78
Free Cash Flow
-72.45-6.27-34.9-46.54-57.5
FCF Margin
---349012.97%-62055.57%-4958.28%
Free Cash Flow Per Share
-6.96-9.72-55.10-88.60-111.76
Levered Free Cash Flow
-150.15-28.42-39.33-51.23-64.34
Unlevered Free Cash Flow
-148.84-30.58-41.7-51.94-64.36
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q